Skip to content

ECHO Diabetes FQHC

Extension for Community Health Outcomes (ECHO) Diabetes Federally Qualified Health Centers (FQHCs)

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07417865
Enrollment
18
Registered
2026-02-18
Start date
2026-01-22
Completion date
2028-07-31
Last updated
2026-02-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes

Keywords

ECHO

Brief summary

Extension for Community Health Outcomes Diabetes FQHC will provide tele-education to primary care providers (PCP) in Federally Qualified Health Centers in the U.S. using the "hub" and "spoke" training model established in the Project ECHO model. Participating FQHCs (called "spokes") will receive twice monthly tele-education sessions delivered by UF's "hub" team in a 6-month program. The program will be evaluated using pre/posttest provider-level surveys and center-level aggregate data in a stepped-wedge trial design with 3 cohorts of FQHCs. The primary outcomes are the proportion of people \>9% HbA1c and technology use (CGM and insulin pump).

Detailed description

We will implement a national ECHO Diabetes FQHC program by offering a 6-month tele-education intervention that includes: (1) a virtual orientation and onboarding for FQHCs (2) one-hour tele-ECHO sessions twice monthly with continuing medical education (CME) credits provided (3) real-time support with complex medical decision-making and (4) access to an online repository of diabetes resources for PCPs. The 'hub' team delivering the ECHO Diabetes FQHC program are a nationally recognized multidisciplinary team of adult and pediatric endocrinologists, a clinical health psychologist, Certified Diabetes Care and Education Specialists (CDCES), a registered dietitian, a Certified Exercise Physiologist (CEP), a medical sociologist, PCPs, and health services researchers. We will evaluate the ECHO Diabetes FQHC program with a stepped-wedge design. This proposal will leverage and expand on key community partnerships established through ECHO Diabetes with two Health Center Controlled Networks (HCCNs), HealthChoiceNetwork (HCN) and AllianceChicago (AC) to accomplish both specific aims. These two Health Center Controlled Networks (HCCNs) have over 100 FQHCs in 29 different states and hold a central data repository for over 7 million unduplicated patients seen for care across these locations. 18 new "spokes" will be recruited from HCN and AC's national network. Covariate-constrained randomization will be used to assign spokes to three cohorts that will have staggered and phased entry into the program in 6-month intervals. Pre- and post-intervention data will be collected at the provider-level and center-level (i.e., "spoke-level") and housed using REDCap® as a central data repository. Provider-level data will include pre and post surveys assessing confidence and knowledge in diabetes care as well as self-reported diabetes care practices. Spoke-level data will include aggregate Health Effectiveness Data and Information Set (HEDIS) metrics for diabetes, Uniform Data System (UDS) metrics for diabetes, mean HbA1c for demographic subgroups, diabetes technology use (CGM and insulin pumps), and referrals for GLP1 and SGL2 medications.

Interventions

BEHAVIORALECHO Diabetes tele-education

All cohorts will be given the ECHO Diabetes tele-education program -- one hour sessions twice monthly for 6 months for PCP in FQHCs

Sponsors

University of Florida
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Federally Qualified Health centers (spokes) are eligible to participate that are part of Health Choice Network (HCN) or Alliance Chicago (AC). All people living with diabetes 18 and older are included in aggregate data sharing to evaluate outcomes. \-

Exclusion criteria

* Non FQHC, not part of HCN or AC

Design outcomes

Primary

MeasureTime frameDescription
HEDIS >9% HbA1cFrom baseline to 12-months followingProportion of FQHC population with \>9% HbA1c
Technology UseFrom baseline to 12-months followingCGM and Pump Use

Countries

United States

Contacts

CONTACTAshby F Walker, Ph.D.
afwalker@ufl.edu352-273-8278
PRINCIPAL_INVESTIGATORAshby F Walker, Ph.D.

University of Florida

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 19, 2026